KRAS and lung cancer: Targeted therapies that suppress oncogenic signaling are increasingly used to treat non–small cell lung cancer with driver mutations (currently in EGFR, KRAS, ALK, RET, ROS1, NTRK, BRAF, ERBB2, and MET; ref. 1).